802 related articles for article (PubMed ID: 34781735)
21. Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency.
Dheekollu J; Malecka K; Wiedmer A; Delecluse HJ; Chiang AK; Altieri DC; Messick TE; Lieberman PM
Oncotarget; 2017 Jan; 8(5):7248-7264. PubMed ID: 28077791
[TBL] [Abstract][Full Text] [Related]
22. The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas.
Xu ZG; Iwatsuki K; Oyama N; Ohtsuka M; Satoh M; Kikuchi S; Akiba H; Kaneko F
Br J Cancer; 2001 Apr; 84(7):920-5. PubMed ID: 11286472
[TBL] [Abstract][Full Text] [Related]
23. Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and γδ T cells.
Djaoud Z; Guethlein LA; Horowitz A; Azzi T; Nemat-Gorgani N; Olive D; Nadal D; Norman PJ; Münz C; Parham P
J Exp Med; 2017 Jun; 214(6):1827-1841. PubMed ID: 28468758
[TBL] [Abstract][Full Text] [Related]
24. Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy.
Rød BE; Wergeland S; Bjørnevik K; Holmøy T; Ulvestad E; Njølstad G; Myhr KM; Torkildsen Ø
Mult Scler Relat Disord; 2023 Nov; 79():105037. PubMed ID: 37804765
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
[TBL] [Abstract][Full Text] [Related]
26. Contributions of the Epstein-Barr virus EBNA1 protein to gastric carcinoma.
Sivachandran N; Dawson CW; Young LS; Liu FF; Middeldorp J; Frappier L
J Virol; 2012 Jan; 86(1):60-8. PubMed ID: 22013060
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus coinfection in children boosts cytomegalovirus-induced differentiation of natural killer cells.
Saghafian-Hedengren S; Sohlberg E; Theorell J; Carvalho-Queiroz C; Nagy N; Persson JO; Nilsson C; Bryceson YT; Sverremark-Ekström E
J Virol; 2013 Dec; 87(24):13446-55. PubMed ID: 24089567
[TBL] [Abstract][Full Text] [Related]
28. Tonsillar CD56brightNKG2A+ NK cells restrict primary Epstein-Barr virus infection in B cells via IFN-γ.
Jud A; Kotur M; Berger C; Gysin C; Nadal D; Lünemann A
Oncotarget; 2017 Jan; 8(4):6130-6141. PubMed ID: 28008151
[TBL] [Abstract][Full Text] [Related]
29. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
Münz C; Bickham KL; Subklewe M; Tsang ML; Chahroudi A; Kurilla MG; Zhang D; O'Donnell M; Steinman RM
J Exp Med; 2000 May; 191(10):1649-60. PubMed ID: 10811859
[TBL] [Abstract][Full Text] [Related]
30. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
Kalla M; Hammerschmidt W
Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
[TBL] [Abstract][Full Text] [Related]
31. Distribution and phenotype of Epstein-Barr virus-infected cells in human pharyngeal tonsils.
Hudnall SD; Ge Y; Wei L; Yang NP; Wang HQ; Chen T
Mod Pathol; 2005 Apr; 18(4):519-27. PubMed ID: 15696119
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer.
Mansouri S; Pan Q; Blencowe BJ; Claycomb JM; Frappier L
J Virol; 2014 Oct; 88(19):11166-77. PubMed ID: 25031339
[TBL] [Abstract][Full Text] [Related]
33. Natural Killer cell transcriptome during primary EBV infection and EBV associated Hodgkin Lymphoma in children-A preliminary observation.
M A; Chatterjee S; A P; S M; Davuluri S; Ar AK; T A; M P; Cs P; Sinha M; Chugani A; R VP; Kk A; R S J
Immunobiology; 2020 May; 225(3):151907. PubMed ID: 32044149
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin.
Lu J; Murakami M; Verma SC; Cai Q; Haldar S; Kaul R; Wasik MA; Middeldorp J; Robertson ES
Virology; 2011 Feb; 410(1):64-75. PubMed ID: 21093004
[TBL] [Abstract][Full Text] [Related]
35. Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.
Nikiforow S; Bottomly K; Miller G; Münz C
J Virol; 2003 Nov; 77(22):12088-104. PubMed ID: 14581546
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
Albanese M; Tagawa T; Bouvet M; Maliqi L; Lutter D; Hoser J; Hastreiter M; Hayes M; Sugden B; Martin L; Moosmann A; Hammerschmidt W
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6467-E6475. PubMed ID: 27698133
[TBL] [Abstract][Full Text] [Related]
37. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
[TBL] [Abstract][Full Text] [Related]
38. Innate immune responses against Epstein Barr virus infection.
Chijioke O; Azzi T; Nadal D; Münz C
J Leukoc Biol; 2013 Dec; 94(6):1185-90. PubMed ID: 23812328
[TBL] [Abstract][Full Text] [Related]
39. Widespread sequence variation in Epstein-Barr virus nuclear antigen 1 influences the antiviral T cell response.
Bell MJ; Brennan R; Miles JJ; Moss DJ; Burrows JM; Burrows SR
J Infect Dis; 2008 Jun; 197(11):1594-7. PubMed ID: 18419576
[TBL] [Abstract][Full Text] [Related]
40. An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model.
Romero-Masters JC; Ohashi M; Djavadian R; Eichelberg MR; Hayes M; Bristol JA; Ma S; Ranheim EA; Gumperz J; Johannsen EC; Kenney SC
PLoS Pathog; 2018 Aug; 14(8):e1007221. PubMed ID: 30125329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
